Project Details
Description
A phase 3 randomized, multicenter, multinational, double-blinded study comparing the efficacy and safety of repeated biweekly infusions of neoGAA (GZ402666) and alglucosidase alfa in treatment naive patients with late onset Pompe disease
Status | Finished |
---|---|
Effective start/end date | 6/14/17 → 6/29/20 |
Funding
- GENZYME CORPORATION
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.